<DOC>
	<DOCNO>NCT01440231</DOCNO>
	<brief_summary>Systemic lupus erythematosis ( SLE ) autoimmune disease , mean body 's immune system attack organs tissue . Within immune system , B-cells plasma cell make protein call antibody , autoimmune disease bind one 's tissue thus refer autoantibody . Atacicept block 2 factor body , call BLyS APRIL , important maintenance B-cells plasma cell , thus production antibody . This study ass whether treatment atacicept reduce SLE disease activity . Atacicept still experimental drug , mean available outside clinical trial , potential benefit risk fully determine . A total 175 subject plan randomize ( 35 subject per treatment arm ) 1:1:1:1:1 ratio receive either atacicept 5 mg , atacicept 25 mg , atacicept 75 mg , atacicept 115 mg match placebo , give subcutaneously weekly 24 week . The primary objective trial evaluate efficacy atacicept compare placebo reduce SLE disease activity subject treat standard care ( SoC ) therapy investigate dose-response relationship . The secondary objective trial : - To evaluate effect atacicept reduce corticosteroid usage - To evaluate safety tolerability profile atacicept subject SLE - To confirm PK PD profile atacicept SLE subject - To evaluate change Medical Outcomes Study Short Form General Health Survey [ SF-36 ] .</brief_summary>
	<brief_title>Atacicept Demonstrating Dose RESponSe</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Male female ≥18 year age Written inform consent Diagnosis SLE satisfy least 4 11 ACR criterion course illness Disease duration least 6 month SLEDAI2K score ≥ 6 screen Positive test result antinuclear antibody ( ANA ) ( HEp2 ANA ≥1:80 ) and/or antidoublestranded deoxyribonucleic acid ( dsDNA ) ( ≥30 IU/mL ) screen Negative serum pregnancy test highly effective method contraception woman childbearing potential . Increase dose corticosteroid within 2 week prior screen Introduction MMF within 3 month prior TD1 increase dose within 1 month screen Change dose immunosuppressant corticosteroid screen period Serum IgG &lt; 6g/L Estimated Glomerular Filtration Rate ( GFR ) &lt; 50 mL/min/1.73m² Urinary protein : creatinine ratio &gt; 2 mg/mg History demyelinate disease Breastfeeding pregnancy Legal limit legal capacity Additional exclusion criterion also apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Rheumatology</keyword>
	<keyword>Double-Blind</keyword>
	<keyword>Placebo-Controlled</keyword>
	<keyword>Multidose</keyword>
	<keyword>Dose-Response</keyword>
	<keyword>Phase II</keyword>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>SLE</keyword>
	<keyword>Atacicept</keyword>
</DOC>